The agenda item on next-generation sequencing at the recent J.P. Morgan Healthcare conference was highly appropriate given the spate of activities that took place in that field leading up to and during the event. On the opening day, for example, big pharma Roche AG, of Basel, Switzerland, revealed it was acquiring a majority ownership in Foundation Medicine Inc. (FMI) in a transaction valued at up to $1.05 billion.
If we thought that biotech's record financing year would be a tough act to follow we might have to revise that notion if the transactions that have been completed so far this month are anything to go by.
SAN FRANCISCO – Although it is still early days, next-generation sequencing (NGS) is being harnessed by researchers and clinicians to help them delve into the complexities of the molecular basis of diseases in order to reveal a patient's genomic profile and how that information relates to the causes of their conditions.
SAN FRANCISCO – We have just come off a record year in the dealmaking milieu with biopharmaceutical mergers and acquisitions (M&As) racking up a total of more than $200 billion in collective value. That amount was well over twice the average annual deal volume recorded in the last decade, according to EY’s Firepower Index and Growth Gap Report 2015: Firepower fireworks.
SAN FRANCISCO – The Washington-based Alliance for Regenerative Medicine (ARM) presented its state-of-the-industry briefing at the Biotech Showcase meeting last week, which re-affirmed the regenerative medicine and advanced therapies industry is extremely vibrant.
SAN FRANCISCO - With all the leading biotechnology and big pharma companies presenting to packed audiences at the J.P. Morgan Healthcare Conference that concluded last Thursday, was all this concentrated intelligence enough to move biotech’s market valuation during the course of the event?
SAN FRANCISCO – The word "revolution" is often overused in the biotech industry, but when it comes to the immuno-oncology sector it is an appropriate description. The science is transformative and has already led to several breakthrough – and potential blockbuster – cancer drugs.
SAN FRANCISCO – Last year at this time the regenerative medicine and advanced therapies industry had begun its coming-out party riding a wave of promising clinical data readouts that ignited strong investor interest and catalyzed involvement and interest from big pharma companies.
SAN FRANCISCO – The mood heading into the start of the 33rd annual J.P. Morgan Healthcare Conference in San Francisco that opens today will be decidedly upbeat. In fact, it will be hard for biotech executives to stop smiling with the industry coming off a record year in terms of raising capital, performance on the capital markets and partnering and mergers and acquisitions. Equally gratifying is that all signs are pointing toward another repeat performance this year.
SAN FRANCISCO – The mood heading into the start of the 33rd annual J.P. Morgan Healthcare Conference in San Francisco that opens today will be decidedly upbeat. In fact, it will be hard for biopharma executives to stop smiling with the industry coming off a record year in terms of raising capital, performance on the capital markets and partnering and mergers and acquisitions.
